| Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... | 128 | 2020 |
| IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... Medrxiv, 2020.04. 01.20048561, 2020 | 87 | 2020 |
| Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 G Gritti, F Raimondi, B Bottazzi, D Ripamonti, I Riva, F Landi, L Alborghetti, ... Leukemia 35 (9), 2710-2714, 2021 | 52 | 2021 |
| The changing pattern of bacterial and fungal respiratory isolates in patients with and without COVID-19 admitted to intensive care unit G Zuglian, D Ripamonti, A Tebaldi, M Cuntrò, I Riva, C Farina, M Rizzi BMC Infectious Diseases 22 (1), 185, 2022 | 11 | 2022 |
| Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure M Damiani, L Gandini, F Landi, G Borleri, F Fabretti, G Gritti, I Riva Respiratory Medicine 185, 2021 | 11 | 2021 |
| Effect of hemoadsorption for cytokine removal in pneumococcal and meningococcal sepsis F Leonardis, V De Angelis, F Frisardi, C Pietrafitta, I Riva, TM Valetti, ... Case Reports in Critical Care 2018 (1), 1205613, 2018 | 11 | 2018 |
| Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv 2020 G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... Google Scholar][CrossRef][Green Version], 0 | 7 | |
| Extracorporeal liver support techniques: a comparison FF Ivano Riva, Antonella Marino, Tino Martino Valetti, Gianmariano Marchesi Journal of artificial organs, 2023 | 5 | 2023 |
| Impact of COVID‐19 on attendances to a major emergency department: an Italian perspective. E Rausa, ME Kelly, R Manfredi, I Riva, A Lucianetti Internal Medicine Journal 50 (9), 2020 | 5 | 2020 |
| Worsening of gas exchange parameters at high FiO2 in COVID-19: misleading or informative? F Raimondi, L Novelli, G Marchesi, F Fabretti, L Grazioli, I Riva, C Allegri, ... Multidisciplinary respiratory medicine 16 (1), 2021 | 2 | 2021 |
| Clarification on the efficacy of extracorporeal purification techniques in critically-ill patients with liver dysfunction I Riva, S Faenza Blood Purification, 2024 | | 2024 |
| The Changing Pattern of Bacterial and Fungal Respiratory Isolates in Patients with COVID-19 Admitted to Intensive Care Unit G Zuglian, D Ripamonti, A Tebaldi, M Cuntrò, I Riva, C Farina, M Rizzi | | 2021 |
| Extracorporeal Cytokine Hemadsorption in Severe COVID-19 Respiratory Failure (preprint) M Damiani, L Gandini, F Landi, F Fabretti, G Gritti, I Riva | | 2020 |
| La procalcitonina quale indicatore di efficacia della terapia antibiotica nelle polmoniti in terapia intensiva I Riva, M Amer, CP Tosi, A Goglio, G Marchesi Microbiologia Medica 22 (3), 2007 | | 2007 |
| CytoSorb in Sever malaria infection: useful or harmful? A case report C Di Martino, A Volontè, L Fagnani, I Riva, A Marino, F Fabretti | | |
| Pancreatin Stone Protein (PSP) as antibiotic therapy marker D Filippi, I Riva, P Ferrari, FA Rasulo, A Marino, F Fabretti | | |
